BioSpace News Archive

InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, will present at the 9th Annual SVB Leerink Global Healthcare Conference February 25-27, 2020 at the Lotte New York Palace in New York, NY, USA.

Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro-diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, today announced that it has received a notice of allowance from the European Patent Office (EPO) covering the use of Todos’ proprietary Total Biochemical Infrared Analysis (TBIA) platform to identify solid tumors using peripheral blood mononuclear cells (PBMCs).

LifeOmic, the creator of the LIFE mobile apps and the Precision Health Cloud (PHC) platform in use at major medical and cancer centers, today announced Ed Simcox as its new chief strategy officer.

Blue Cross Blue Shield of Massachusetts named six substance use treatment and recovery centers in its network as Blue Distinction® Centers for Substance Use Treatment and Recovery – a new designation under the Blue Distinction Specialty Care program.

The Trendlines Group Ltd., is pleased to announce that its newly-formed fund, Trendlines Agrifood Fund Pte. Ltd., has made its first investment, investing in Equinom Ltd, a seed breeding technology business..

Patients Significantly Reduced Hypoglycemic and High Glycemic Events by 50% and 40%, respectively, over a Two-Year Period

FREMONT, Calif. , Feb. 19, 2020 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX) today announced that Mike Raab , president and chief executive officer of Ardelyx, will present at the 9 th Annual SVB Leerink Global Healthcare Conference at 3:30 p.m. ET on Wednesday , Feb. 26, 2020 in New York City . To access the live webcast of Ardely

Feb. 19, 2020 13:00 UTC Presentation and webcast to take place at 9:00 a.m. ET on February 26 CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving health, today announced that management will be presenting at the SVB Leerink 9th Annual Global Healthcare Conference in New York City on February 26,

Myomo, Inc. announced that it has signed an agreement with HOMELINK which will enable Myomo to process out-of-network claims for its MyoPro powered orthosis with the 1,200 payers in HOMELINK’s network.

Catalent, Inc. announced that its wholly owned subsidiary, Catalent Pharma Solutions, Inc., intends to offer, subject to market and other conditions, €450.0 million in aggregate principal amount of senior unsecured notes due 2028 in a private offering that is exempt from the registration requirements of the Securities Act of 1933, as amended.